Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses using Duodart (dutasteride + tamsulosin) for hair loss, with side effects like frequent urination and ejaculation issues leading to discontinuation. The user switched to German Avodart and experienced mood and erection side effects, considering adjusting the dosage to three times a week.

The user is starting dutasteride mesotherapy and seeks information on checking serum DHT levels in Germany. They previously tried finasteride but experienced unpleasant side effects.

A 31-year-old male experienced side effects from various hair loss treatments, including finasteride and dutasteride, and is considering mesotherapy with dutasteride as a last resort. Another user tried mesotherapy for four months without significant change but experienced no side effects.

Dutasteride is more effective in gel capsule form due to better absorption, as it is fat-soluble. If only pills are available, taking them with fat or increasing the dose slightly may help.

A user is experiencing facial bloating from low-dose topical finasteride due to high estradiol levels and is seeking advice on using DIM to manage this issue, including dosage and brand recommendations.

Breezula, a topical treatment, is anticipated to be available in the US by mid-2027 as a potential alternative to finasteride with fewer systemic side effects. There is ongoing debate about its effectiveness and some users report similar side effects to finasteride.

The user has been using oral minoxidil and dutasteride for hair loss without success and is considering adding topical 17α-estradiol, Pyrilutamide, Clascoterone, or cetirizine. They have confirmed low serum DHT levels and are exploring additional treatments due to genetic sensitivity to DHT and prostaglandin D2.

After gyno surgery, OP is considering restarting finasteride at a lower dose (0.25mg/0.5mg) or switching to topical to reduce the risk of gyno recurrence. Lower doses and topical application may lessen side effects due to reduced systemic absorption.

People who have not responded to finasteride (Fin) switching to dutasteride for hair loss treatment and their experiences with the switch. Other treatments such as Minoxidil (Min) and RU58841 are also discussed.

Woman uses antiandrogens for hair thinning prevention, experiences severe dry eye with finasteride. Asks if dutasteride could be better despite potential for worse dry eye.

27F with androgenic alopecia since 17 seeks treatment. Tried spironolactone, caused low blood pressure; believes finasteride is safer and wants to try it.

A user experienced sexual side effects, including reduced semen production and numbness, after switching from finasteride to dutasteride for hair loss. They decided to stop dutasteride to prioritize their sexual health and may return to finasteride if issues resolve.

A 19-year-old male is experiencing accelerated hair recession after two months on oral Dutasteride, despite no noticeable shedding, while also using topical Minoxidil and Finasteride. He is unsure if the treatment is effective and is unable to access RU58841.

Dutasteride and finasteride for hair loss, with dissatisfaction expressed about dutasteride and consideration of switching back to finasteride. Users share varied experiences, noting individual responses to treatments differ.

The user is considering RU58841 and has been using dutasteride since age 17. They are seeking affordable SARD options, mentioning ASC-J9, GT20029, and AH001.

Dutasteride mesotherapy combined with topical minoxidil led to some hair regrowth, but taking dutasteride pills every 2-3 days showed more noticeable results. The user did not try finasteride, as their dermatologist recommended dutasteride for better outcomes with fewer side effects at a reduced dosage.

The conversation is about a user struggling with hair loss despite using dutasteride, finasteride, minoxidil, and dermaneedling. The user is considering other treatments but is hesitant to use RU-58841 due to side effects and is seeking advice on alternative solutions.

A user is using a Finoxidil topical spray and is curious if oral Finasteride would be more effective, considering they are already on a DHT blocker called Cyproterone. They are concerned about the potential impact of oral Finasteride on their transition.

A 49-year-old male switched from Finasteride to Dutasteride 2.5 mg daily, along with oral Minoxidil 5 mg, resulting in significant hair regrowth and stopping hair loss after six months. Despite initial side effects like adrenaline spikes and urinary issues, the user is satisfied with the results and plans to continue the treatment.

A user diagnosed with lymphoma is advised to stop finasteride during chemotherapy, with suggestions to consider treatments like Dutasteride and Minoxidil post-recovery. The focus is on prioritizing health over hair loss, with encouragement and advice from others who have experienced similar situations.

New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.

The conversation is about finding providers for Dutasteride Mesotherapy in the US, which is more common in Europe. The user is asking if any mesotherapy/PRP clinic could offer it if they provide the Dutasteride.

Clascoterone phase 3 results show promising improvements in hair count, but concerns about high costs and lack of detailed data remain. Users compare it to existing treatments like Minoxidil and Finasteride, expressing skepticism about its accessibility and effectiveness.

Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.

A dermatologist prescribed 0.5mg dutasteride every two days and 5mg Minoxidil daily for hair loss, suggesting dutasteride mesotherapy as an alternative. The discussion questions the effectiveness and cost of mesotherapy compared to oral treatments, with concerns about side effects and the dermatologist's approach.

The conversation is about experiences with Dutasteride Mesotherapy and its symptoms compared to oral dutasteride. Users discuss the effectiveness and side effects of this treatment for hair loss.

Finasteride and Dutasteride are under review in the EU due to concerns about side effects like depression, but they are unlikely to be banned. Access to these medications varies, with easier availability in the UK compared to some EU countries.

Trans women discuss using finasteride and dutasteride for hair loss and whether to continue after testosterone suppression. One user reduced dutasteride dosage after achieving undetectable testosterone levels.

The conversation discusses hair loss treatments, specifically using dutasteride (0.5mg daily) with no side effects reported after two months. It also mentions the health benefits of one meal per day and the low incidence of side effects.

Using DIM and Calcium D-Glucarate to reduce finasteride side effects. Discussion includes dosage, brand, and product effectiveness.